Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced recent highlights and reported fourth quarter and full year 2021 financial results.
- This is an exciting time for Annexon, and I am confident in our potential to deliver game-changing medicines to patients in need.
- Annexon anticipates reporting data from all patients treated, including data from the three-month follow-up period, in the second quarter of 2022.
- In addition, Annexon reported preclinical data supporting the potential role of the complement pathway in warm autoimmune hemolytic anemia (wAIHA).
- Annexon continues to expect that its current cash position is sufficient to fund its operating plans into the first quarter of 2024.